CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 500 filers reported holding CRISPR THERAPEUTICS AG in Q2 2021. The put-call ratio across all filers is 1.18 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $261,673 | -19.0% | 5,765 | +6.1% | 0.21% | -15.4% |
| Q2 2023 | $322,973 | +47.9% | 5,435 | +12.6% | 0.25% | +108.5% |
| Q1 2023 | $218,369 | -41.5% | 4,828 | -15.5% | 0.12% | -71.1% |
| Q3 2022 | $373,000 | -17.7% | 5,714 | -23.4% | 0.41% | -19.8% |
| Q2 2022 | $453,000 | -1.5% | 7,462 | +1.6% | 0.51% | +7.8% |
| Q1 2022 | $460,000 | -3.4% | 7,341 | +16.9% | 0.47% | -1.0% |
| Q4 2021 | $476,000 | -53.0% | 6,282 | -17.0% | 0.48% | -12.9% |
| Q1 2021 | $1,012,000 | -32.2% | 7,568 | -22.4% | 0.55% | -32.2% |
| Q4 2020 | $1,493,000 | – | 9,753 | – | 0.81% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $32,581,000 | 55.55% |
| NEA Management Company, LLC | 1,590,002 | $103,907,000 | 5.19% |
| ARK Investment Management | 8,237,122 | $538,296,000 | 3.75% |
| Nikko Asset Management Americas, Inc. | 4,262,736 | $277,078,000 | 3.54% |
| CLOUGH CAPITAL PARTNERS L P | 414,767 | $27,105,000 | 2.89% |
| Integral Health Asset Management, LLC | 220,000 | $14,377,000 | 2.79% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,268,000 | 2.48% |
| HC Advisors, LLC | 53,944 | $3,525,000 | 2.43% |
| Green Alpha Advisors, LLC | 27,466 | $1,795,000 | 1.52% |
| EFG Asset Management (North America) Corp. | 84,356 | $5,516,000 | 1.28% |